Infectious Disease Control

CGTN: Vitality under COVID-19: China's smart ports aid increased throughput

BEIJING, Dec. 29, 2022 /PRNewswire/ -- China's Qingdao Port, a subsidiary of Shandong Port Group and the second-largest foreign trade port in eastChina's Shandong Province, has seen an increase in anchorage rotations of very large container ships, according to China Media Group. The port has han...

2022-12-29 11:55 6898

Global Times: Three years' hard effort to fight COVID-19 'worthwhile'

BEIJING, Dec. 28, 2022 /PRNewswire/ -- After three years' hard effort to keep the COVID-19 at bay,China has optimized its virus responses recently. The Global Times has talked with front line medical workers, grass-roots community workers and others about their experience in the three-year battle...

2022-12-28 21:38 1967

CGTN: Vitality under COVID-19: China gears up for medical supplies

BEIJING, Dec. 28, 2022 /PRNewswire/ -- China has made efforts to ensure the medical supplies needed for COVID-19 prevention and control after it loosened its epidemic measures in early December, which was followed by an increase in infections and surging demand for medicines. The country's Natio...

2022-12-28 00:13 6648

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...

2022-12-27 20:00 2728

China to downgrade COVID-19 management to Class B

BEIJING, Dec. 27, 2022 /PRNewswire/ -- A report from People's Daily: China will downgrade management of COVID-19 to Class B and cancel quarantine requirements on inbound travelers fromJan. 8, 2023, China's top health authority announced recently. In a statement released late Monday, the National...

2022-12-27 18:06 2240

Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification

* Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's COVID-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets * With the launch of Nirmacom, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India HYDERABAD, India, Dec. 27, ...

2022-12-27 10:00 3342

China actively optimizes COVID-19 response measures to better prepare for challenges

BEIJING, Dec. 26, 2022 /PRNewswire/ -- As multiple regions in China have seen surging COVID-19 infections, local governments are taking swift and precise measures to prevent severe cases, protect people's health, and build a barrier against the epidemic. These measures include providing timely m...

2022-12-26 14:32 3123

CGTN: 'New Approaches': How China stepped up its COVID-19 treatments

BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helpedChina evade...

2022-12-21 18:51 2169

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

BEIJING, Dec. 20, 2022 /PRNewswire/ -- China now has been enhancing its COVID-19 vaccination as a priority especially among the vulnerable groups such as elders to further cement its protection for people against the virus. This strategy is becoming more prominent as the country has loosened up i...

2022-12-20 22:53 2525

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...

2022-12-20 19:21 1780

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

BEIJING, Dec. 20, 2022 /PRNewswire/ -- SARS-CoV-2, the virus causing COVID-19, mutates constantly. Since the beginning of the pandemic three years ago, the virus has hit the world with different faces – Alpha, Beta, Delta, Gamma and then Omicron – taking away millions of lives. Wu Zunyou, chief ...

2022-12-20 10:59 1903

Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, fr...

2022-12-19 13:53 2033

Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product

SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistica...

2022-12-16 01:30 1914

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of$125 million aggregate principal amount of convertible...

2022-12-15 23:43 3388

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

ACC, NCCN, ACS, and CHAI collaborate to launch new NCCN Harmonized Guidelines for Sub-Saharan Africa focused on pediatric cancers; available free at NCCN.org/harmonized. DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NC...

2022-12-15 14:07 1630

Stemirna receives Emergency Use Authorization from Laos for its proprietary mRNA vaccine

SHANGHAI, Dec. 14, 2022 /PRNewswire/ -- On December 8, 2022, Stemirna Therapeutics Co., Ltd. (Stemirna), a Chinese biotech startup specialized inmRNA technology-based drug development, received an Emergency Use Authorization (EUA) from the Food and Drug Department under the Ministry of Health of ...

2022-12-15 12:27 3412

CGTN: How China strengthens vaccine cooperation to battle COVID-19

BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three y...

2022-12-15 09:16 2345

Novavax Announces Proposed $125 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...

2022-12-15 05:39 3187

E-Home Household Services Holdings Limited's subsidiary Zhong Run Launches Cloud Pharmacy Service to Address New Situation of Epidemic Prevention and Control

FUZHOU, China, Dec. 14, 2022 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced that the Company's subsidiary Zhongrun (Fujian) Pharmaceutical Co., Ltd. ("Zhongrun") plan to expa...

2022-12-14 21:30 2416

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...

2022-12-14 15:17 3849
1 ... 45678910 ... 78

Week's Top Stories